Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

4.405 +0.375 (+9.31%)
Delayed Quote Updated: 2:48 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Ironwood Pharma Stock Draws Retail Investor Ire With Big Q1 Miss And No Earnings Call ↗
The drugmaker’s first-quarter revenue of $41.1 million came in well below the consensus estimate of $56.7 million, attributed to changes in AbbVie’s gross-to-net rebate reserves. 
Via Stocktwits
Topics Earnings
News headline image
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview: Ironwood Pharmaceuticals ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug ↗
Ironwood must run a new Phase 3 trial after FDA talks, delaying its SBS drug approval despite strong results from prior studies. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Moves Lower; M&T Bank Earnings Miss Views ↗
 
Via Benzinga
Topics Earnings
News headline image
Gapping stocks in Monday's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
These stocks are moving in today's pre-market session ↗
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Top stock movements in today's session. ↗
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
News headline image
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.